Brief: Transcode Therapeutics Announces Prolonged Survival In Murine Models With Glioblastoma Treated With Its Lead Candidate, Ttx-Mc138
26/10/2023 13:29
Oct 26 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES PROLONGED SURVIVAL IN
MURINE
MODELS WITH GLIOBLASTOMA TREATED WITH ITS LEAD CANDIDATE,
TTX-MC138
* TRANSCODE THERAPEUTICS INC - TTX-MC138 WAS SUCCESSFULLY
DELIVERED AND DEMONSTRATED PRELIMINARY EFFICACY IN SPONTANEOUS
FELINE MAMMARY CARCINOMA
Source text for Eikon: ID:nGNX8vLFHN
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors